Baxter Ventures

Developer of a needle-free injector designed to deliver generation of proactive, accessible and personalized medicines for age-related diseases. The company's technology consists of an artificial intelligence-driven health span diagnostic system, a needleless medication delivery medical device and a preventive healthcare center to treat age-related diseases, enabling doctors to overturn aging by preventing chronic diseases and immune system disorders.

Medically Home Group, Inc., based in Boston, Massachusetts, offers a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on providing patient-centered care for individuals with serious or complex illnesses, including conditions such as heart failure, pneumonia, urinary tract infections, cellulitis, and respiratory issues. Medically Home's innovative model enables the safe transition of medical care from traditional hospital settings to patients' homes, allowing for centralized, on-demand management of acute medical needs. This approach connects patients with caregivers while facilitating monitoring and communication, ensuring that patients and their families receive comprehensive support in a familiar environment.

Walela is a company focused on advancing maternal and fetal health diagnostics through innovative sensor technology. Their specialized medical devices are designed to measure fetal heart rate and blood pH levels, providing critical information to expectant mothers and healthcare professionals. By offering enhanced diagnostic capabilities, Walela aims to improve fetal and maternal health outcomes while potentially reducing the incidence of unnecessary cesarean sections.

Hospital IQ LLC specializes in developing cloud-based software aimed at enhancing operational efficiency in hospitals. The company offers a predictive analytics platform that optimizes surgical scheduling, inpatient capacity, and discharge processes while reducing wait times and length of stay. By combining artificial intelligence, machine learning, and advanced data analytics, the platform provides hospital administrators and clinical department heads with actionable insights to improve decision-making and resource allocation. Hospital IQ's solutions are designed to streamline operations, improve patient flow, and ultimately enhance clinical outcomes and financial performance. Founded in 2013 and based in Newton, Massachusetts, Hospital IQ collaborates with leading healthcare institutions to address operational challenges and support quality improvement initiatives.

Alvotech is a biopharmaceutical company that specializes in the development and manufacture of biosimilar medicines aimed at treating severe and chronic conditions. Founded in 2013 and headquartered in Reykjavík, Iceland, with additional facilities in Germany and Switzerland, Alvotech focuses on creating biosimilar versions of leading monoclonal antibodies. The company has six key biosimilar molecules in its development pipeline and has invested over $500 million in this endeavor. Alvotech aims to enhance patient access to effective treatments and improve the overall quality of life for individuals facing various health challenges. In pursuit of its goals, Alvotech has established strategic partnerships with prominent global pharmaceutical companies to facilitate the commercialization of its products.

MedaSense Biometrics Ltd. develops pain monitoring medical devices. Its PMD-200, an objective monitoring device that quantifies patients physiological response to pain. The company also offers NOL-egde Hub, a center of global collaboration aims to enhance pain research and the development of new products. Its serves to health care givers, researchers, patients, and industry. The company was incorporated in 2008 and is based in Ramat Gan, Israel with additional office in Longmont, Colorado.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing games and applications aimed at managing chronic health conditions and enhancing patient adherence. Founded in 2008, Ayogo utilizes behavioral psychology and social gaming principles to improve health outcomes. Its flagship product, GoodLife, offers a customizable platform featuring gamification elements, incentives, and social interactions to engage users effectively. Additionally, Ayogo's Alternate Reality Games provide a suite of learning applications that blend online and real-world experiences. The company collaborates closely with patients, end-users, and clients, which include insurers, healthcare providers, and pharmaceutical companies. By focusing on psychosocial factors, Ayogo's platform enhances patient activation, adherence, and persistence in treatment, ultimately aiming to foster healthier patients and better financial outcomes for healthcare organizations.

Seprafilm is a mechanical bioresorbable adhesion barrier that is applied to adhesiogenic tissues before surgical closure. It is indicated for the reduction in the incidence, extent, and severity of postoperative adhesions in patients undergoing abdominal or pelvic laparotomy.

Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.

Prescient Surgical, Inc. develops medical devices aimed at preventing surgical site infections, specifically for patients undergoing high-risk abdominal gastrointestinal surgeries. The company's flagship product, CleanCision, features a wound retraction and protection system that integrates wound protection with continuous irrigation. This system effectively clears harmful bacteria that may invade surgical incisions, thereby enhancing patient outcomes and reducing healthcare costs. Incorporated in 2012, Prescient Surgical is based in San Carlos, California.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

VitalConnect specializes in wearable biosensor technology aimed at enhancing patient monitoring both in hospitals and remotely. The company utilizes its expertise in biomedical engineering, data analytics, and chip design to develop products that continuously monitor vital signs through an adhesive patch. These innovations include the Vista Solution, which provides healthcare professionals with 24/7 access to patient health data via an online portal, tracking 11 vital signs and offering predictive analytics. The VitalPatch biosensor specifically measures critical parameters such as EKG, heart rate, respiratory rate, and body temperature, facilitating immediate responses to urgent health situations. By combining these technologies, VitalConnect's solutions improve patient mobility and comfort while enabling clinicians to optimize treatment through comprehensive patient insights, ultimately leading to better health outcomes and reduced economic burdens.

Bugworks Research Inc. is a drug discovery company focused on developing antibiotics that address the growing challenge of antimicrobial resistance (AMR). Founded in 2014, the company is headquartered in Saratoga, California, with additional offices in Adelaide, Australia, and Bengaluru, India. Bugworks produces a range of antibiotic products, including GYROX-1, an intravenous drug designed for critical care infections; GYROX-2, an oral solution targeting both hospital and community infections; and GYROX-3, an oral drug specifically for cystic fibrosis patients. Through its innovative research, Bugworks aims to create effective pharmaceutical solutions to combat serious infections and improve patient outcomes.

As of July 27, 2017, Claris Injectables Limited operates as a subsidiary of Baxter International Inc.

Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.

MedaSense Biometrics Ltd. develops pain monitoring medical devices. Its PMD-200, an objective monitoring device that quantifies patients physiological response to pain. The company also offers NOL-egde Hub, a center of global collaboration aims to enhance pain research and the development of new products. Its serves to health care givers, researchers, patients, and industry. The company was incorporated in 2008 and is based in Ramat Gan, Israel with additional office in Longmont, Colorado.

Opsonix is developing and commercializing a pathogen-extracting therapy that uses its proprietary pathogen-capture proteins to remove infectious microbes and the toxins they release from circulating blood, offering a new broad-spectrum approach to transform the treatment of blood-borne infectious diseases, including sepsis.

TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

SuppreMol is a private biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is dedicated to creating innovative treatments aimed at addressing the underlying causes of these disorders, rather than just alleviating their symptoms. SuppreMol's research focuses on soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to possess specific immunoregulatory properties. This approach has the potential to advance the treatment landscape for individuals suffering from autoimmune conditions, offering new hope for more effective and long-lasting solutions.

AesRx (ǽs-r-ex) is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease. AesRx's lead program, Aes-103, is a potential breakthrough in the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can cause red blood cells to deform into rigid sickle shapes that block capillaries and other small blood vessels. This blockage can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.

Chatham Therapeutics LLC operates in the biotechnology sector. The company was formerly known as VECTORRX INC. The company was incorporated in 2010 and is based in Chapel Hill, North Carolina.

Xenetic Biosciences is a biopharmaceutical company based in Framingham, Massachusetts, specializing in the development of innovative oncology therapeutics and biologic drugs. The company is advancing its personalized chimeric antigen receptor T cell (CAR T) platform, XCART, which is designed to target unique tumor neoantigens specific to individual patients. In addition to XCART, Xenetic is developing a DNase platform aimed at enhancing existing cancer treatments by addressing neutrophil extracellular traps, which contribute to cancer progression and treatment resistance. The company's investigational drug candidate, XBIO-101, targets progestin-resistant endometrial cancer. Furthermore, Xenetic leverages its proprietary PolyXen drug delivery platform through collaborations with major pharmaceutical firms, including Takeda Pharmaceutical and Serum Institute of India, to improve drug efficacy and performance across various medical areas, particularly oncology.

Covagen is a biopharmaceutical company that specializes in developing bispecific FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach results in therapeutics with unique modes of action and improved efficacy for treating inflammatory diseases and cancer. Covagen's lead product, COVA322, targets inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company's proprietary platform allows for the customization of FynomAbs by attaching Fynomers at multiple sites on an antibody, enabling tailored therapeutic architectures. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic partnerships, including a collaboration with Mitsubishi Tanabe for developing bispecific FynomAbs against specific target pairs. The company is backed by a consortium of investors, which includes notable names in the life sciences sector.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

The URINFO 2000 fluid monitoring system is the only feasible solution for the accurate, real-time, and continuous monitoring of urine output. The product is based on FlowSense’s patented optical flow sensing technology. URINFO2000 has been used in the critical care setting to optimize fluid and electrolyte balance, treat acute kidney injury, and prevent renal failure.

Gambro is a global medical technology company specializing in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, as well as other extracorporeal treatments for both chronic and acute patients. Founded in 1964, Gambro has been instrumental in advancing dialysis technology, which is crucial for patients unable to receive kidney transplants due to organ shortages. The company offers solutions for in-center care, self-care hemodialysis, peritoneal dialysis, and renal intensive care, while also exploring new applications in liver dialysis. With a workforce of approximately 8,000 employees and production facilities in multiple countries, Gambro serves healthcare providers in over 90 countries. Its commitment to innovation has positioned it as a leader in the dialysis market, enhancing treatment quality and operational efficiency in clinics and intensive care units worldwide.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular diseases and conditions using its proprietary bioresorbable hydrogel technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for managing post-surgical ocular pain and inflammation, as well as allergic conjunctivitis, and is currently in trials for treating dry eye diseases. Other key products in development include OTX-TP, an intracanalicular insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant also targeting intraocular pressure. Additionally, Ocular Therapeutix is exploring various preclinical programs to address acute ocular pain, post-operative inflammation, and other ophthalmic conditions. The company has a strategic collaboration with Regeneron Pharmaceuticals to utilize its hydrogel technology in conjunction with Regeneron’s VEGF-targeting compounds for retinal disease treatments. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

Zytoprotec is an Austrian biotechnology company, founded in 2007 to apply ground-breaking findings in the area of cytoprotection to the development of new treatment options for major disease areas. The Company was founded by a team of professionals that combine extensive experience in business administration, clinical research, pharmaceutical product development, as well as company and patent law.

Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.

Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.

Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. It offers GL-0817 for the prevention of the recurrence of squamous cell cancer of the oral cavity; GL-2045 for the treatment of a range of autoimmune diseases, including low platelet count (ITP), peripheral neuropathy (CIDP), and Myasthenia gravis; and GB-4542, an anti-CD20 monoclonal antibody therapy. Gliknik Inc. was founded in 2007 and is based in Baltimore, Maryland.

Synovis Life Technologies is a medical device company focused on developing innovative solutions for the surgical and interventional treatment of various diseases. The company specializes in implantable biomaterial devices and offers a range of products designed for microsurgery. Its surgical tools aim to reduce risks and facilitate critical procedures, enhancing the safety and effectiveness of surgical interventions. Through its dedication to advancing medical technology, Synovis Life Technologies contributes to improved patient outcomes in the healthcare sector.

Developer and distributor of pharmaceutical delivery equipment intended to handle and administer medications. The company's medical device platform medical devices for preparing, handling, packaging, and administration of liquid medications for use in hospitals, critical care units, and alternate-site pharmacies enabling healthcare providers to treat patients with complete safety and effectiveness.

Prism Pharmaceuticals, Inc., an acute care pharmaceutical company, engages in developing and commercializing cardiovascular injectable products in the United States. Its products include NEXTERONE, an anti arrhythmic agent in the form of injectable amiodarone; and PM103, an intravenous formulation of clopidogrel bisulfate. The company was founded in 2004 and is based in King of Prussia, Pennsylvania.

ApaTech Ltd., an ortho-biologics company, produces synthetic bone repair materials. It offers Actifuse, a synthetic bone graft, which creates a material that promotes the formation of bone and increases the volume of bone formed in the graft/host bone composite structures for small void filling and spinal fusion applications. The company also provides ApaPore, a synthetic and porous hydro-xyapatite grafting for the cemented revision of failed total joint arthroplasties for spinal fusions and fracture fixations, as well as for treating bone defects; and Actifuse MIS Bone Graft Delivery System that offers controlled delivery and precise placement for surgeons performing open and minimally invasive procedures, as well as for use in various spinal and orthopedic procedures, including posterolateral fusion, bone void filling, and acetabular cysts. It offers its products through distributors in the United Kingdom, Ireland, Norway, Sweden, Germany, Austria, Spain, Portugal, Italy, Greece, Turkey, Kuwait, Syria, Australia, and New Zealand. ApaTech Ltd. was founded in 2001 and is based in Elstree, the United Kingdom. It has operations in London, the United Kingdom; Foxborough, Massachusetts; and Berlin, Germany.

Fusion Medical Technologies manufactures proprietary surgical hemostatic sealant products. It develops collagen gel-based products for use in controlling bleeding in a variety of surgeries.

Somatogen is a biotech company developing a genetically engineered blood substitute.

Caremark provides integrated pharmacy health care services in the United States. It operates through pharmacy services and pharmacy retail. Its pharmacy services include pharmacy benefit management services, such as plan design and administration, formulary management, Medicare part D services, mail order and specialty pharmacy services, prescription management systems, clinical services, disease management, retail pharmacy network management services, discounted drug purchase arrangements, and medical spend management services. Its retail segment provides prescription drugs, over-the-counter drugs, beauty products and cosmetics, seasonal merchandise, greeting cards, and convenience foods, and other related services. It currently operates 7,705 retail drugstores, 860 health care clinics, 17 onsite pharmacies, 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies, 4 mail service dispensing pharmacies, and 84 branches, as well as 6 centers of excellence for infusion and antral services. Caremark provides its services to employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. It was established in 1892 and is headquartered in Woonsocket, Rhode Island. Caremark carries out its operations through its subsidaries.